<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206229</url>
  </required_header>
  <id_info>
    <org_study_id>TPI-CL-109-A</org_study_id>
    <nct_id>NCT03206229</nct_id>
  </id_info>
  <brief_title>Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects</brief_title>
  <acronym>TPI-120</acronym>
  <official_title>A Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study Comparing TPI-120 and Neulasta® Administered Through Subcutaneous Route in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adello Biologics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>inVentiv Health Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Adello Biologics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way,&#xD;
      crossover study comparing the Test (T) and Reference (R) products following subcutaneous&#xD;
      administration. Subjects will be randomly assigned to one of two treatments sequences (TR or&#xD;
      RT).&#xD;
&#xD;
      All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol&#xD;
      requirements and procedures will be followed within each group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study design was prepared to assess and compare the PK, PD, safety, tolerability&#xD;
      of the Adello biosimilar candidate, TPI-120 and the US-licensed reference product, Neulasta®&#xD;
      after administering a single subcutaneous 2 mg dose in healthy adult subjects in a crossover&#xD;
      design. The primary PK parameters are AUC0-t, AUC0-inf, and Cmax, and the primary PD&#xD;
      parameters are baseline-corrected AUEC0-t and Emax for ANC.&#xD;
&#xD;
      This is a single or up to 2 centers, double-blind, randomized, single-dose, two-way,&#xD;
      crossover study comparing the Test (T) and Reference (R) products following subcutaneous&#xD;
      administration. Subjects will be randomly assigned to one of two treatments sequences (TR or&#xD;
      RT).&#xD;
&#xD;
      All subjects will be dosed at the CRO's designated clinical site(s) and the same protocol&#xD;
      requirements and procedures will be followed within each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Actual">January 18, 2018</completion_date>
  <primary_completion_date type="Actual">June 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is a Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is double blind study so participat healthy subjects and investigators both would be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>56 days</time_frame>
    <description>To evaluate the pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last non-zero concentration (AUC0-t)</measure>
    <time_frame>56 days</time_frame>
    <description>To evaluate the pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (extrapolated AUC0-inf)</measure>
    <time_frame>56 days</time_frame>
    <description>To evaluate the pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Variable - Tolerability as measured by Injection Site reactions</measure>
    <time_frame>1, 2, 4, and 24 hours postdose during each study period</time_frame>
    <description>Tolerability as measured by Injection Site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Variable - Immunogenicity as measured by presence of Anti Drug Antibodies</measure>
    <time_frame>Day 1 of each study period &amp; Day 22 of each study period</time_frame>
    <description>Immunogenicity as measured by presence of Anti Drug Antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TPI-120 (PEG-rhG-CSF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neulasta (PEG-rhG-CSF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule</description>
    <arm_group_label>TPI-120 (PEG-rhG-CSF)</arm_group_label>
    <other_name>PEGFILGRASTIM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta (PEG-rhG-CSF)</intervention_name>
    <description>PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule</description>
    <arm_group_label>Neulasta (PEG-rhG-CSF)</arm_group_label>
    <other_name>PEGFILGRASTIM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months&#xD;
             prior to dosing), 19 - 55 years of age (inclusive), with body mass index (BMI) ≥ 19&#xD;
             and ≤ 30 kg/m2, and body weight not &lt; 50 kg or &gt; 100 kg at the time of screening.&#xD;
&#xD;
          2. Healthy as defined by:&#xD;
&#xD;
               1. The absence of clinically significant (in the opinion of the PI/designee) illness&#xD;
                  or surgery within 4 weeks prior to dosing.&#xD;
&#xD;
               2. The absence of a clinically significant (in the opinion of the PI/designee)&#xD;
                  history of disease.&#xD;
&#xD;
               3. WBC (white blood cell) &gt; 4.0 x 109/L and &lt; 1.5 times the upper limit of normal&#xD;
                  (ULN), ANC (absolute neutrophil count) &gt; 2.0 x 109/L and &lt; 1.5 times the upper&#xD;
                  limit of normal (ULN), Platelet count &gt; 150 x 109/L, AST (aspartate&#xD;
                  aminotransferase) &lt; 2.5 time the upper limit of normal (ULN), ALT (alanine&#xD;
                  aminotransferase) &lt; 2.5 time the upper limit of normal (ULN), Serum bilirubin &lt;&#xD;
                  1.5 time the upper limit of normal (ULN) and Serum creatinine &lt; 1.5 time the&#xD;
                  upper limit of normal (ULN). [Refer to APPENDIX 1 for normal reference ranges]&#xD;
&#xD;
               4. The absence of febrile (defined by a documented oral temperature of 101.5 °F or&#xD;
                  greater) or infectious illness within 1 week of first dosing.&#xD;
&#xD;
               5. The absence of a clinically significant history of skin disorders, including&#xD;
                  psoriasis.&#xD;
&#xD;
          3. Females of childbearing potential must be willing to use acceptable contraceptive&#xD;
             methods throughout the study, and for 30 days thereafter.&#xD;
&#xD;
          4. Females of non-childbearing potential must have undergone sterilization procedures, at&#xD;
             least 6 months prior to the first dose or be postmenopausal with amenorrhea for at&#xD;
             least 1 year prior to the first dose and follicle-stimulating hormone (FSH) serum&#xD;
             levels consistent with postmenopausal status.&#xD;
&#xD;
          5. Capable of consent.&#xD;
&#xD;
          6. Male subjects willing to follow approved birth control method for the duration of the&#xD;
             study, and for 30 days thereafter, such as (a double barrier method) vasectomy, condom&#xD;
             with spermicide, condom with diaphragm or abstinence, subject should also not donate&#xD;
             sperm during this time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive test for hepatitis B, hepatitis C, or HIV.&#xD;
&#xD;
          2. Illicit/illegal drug use as evidenced by a positive test for alcohol or drug screen at&#xD;
             screening or check -in.&#xD;
&#xD;
          3. Positive result for urine alcohol test at screening or check-in&#xD;
&#xD;
          4. Tobacco use as evidenced by a positive cotinine result at screening or check-in.&#xD;
&#xD;
          5. History of allergic reactions to pegfilgrastim, filgrastim, Escherichia coli (E.&#xD;
             coli)-derived proteins, or other related drugs. History of allergic reactions or&#xD;
             hypersensitivity to acetate/acetic acid, polysorbate 20, or sorbitol.&#xD;
&#xD;
          6. Hereditary fructose intolerance.&#xD;
&#xD;
          7. Females with positive pregnancy tests at screening or check-in.&#xD;
&#xD;
          8. Any reason which, in the opinion of the Investigator, would prevent the subject from&#xD;
             participating in the study or completing follow-up activities.&#xD;
&#xD;
          9. Clinically significant ECG or vital sign abnormalities at screening.&#xD;
&#xD;
         10. History of significant alcohol abuse within one year prior to initial dosing or&#xD;
             regular use of alcohol (more than 14 units of alcohol per week) within six months&#xD;
             prior to initial dosing.&#xD;
&#xD;
         11. History of drug abuse or use of illicit/illegal drugs within 1 year prior to initial&#xD;
             dosing.&#xD;
&#xD;
         12. No medications are permitted during the study. Exceptions are:&#xD;
&#xD;
               1. Hormonal contraceptives and Hormone Replacement Therapy (HRT),&#xD;
&#xD;
               2. Thyroid replacement therapy i.e., liothyronine (T3) or levothyroxine (T4).&#xD;
&#xD;
               3. Acetaminophen&#xD;
&#xD;
         13. Donation of plasma within 7 days of dosing; blood donation or significant loss of&#xD;
             blood within 30 days of dosing.&#xD;
&#xD;
         14. Participation in a clinical trial involving the administration of an investigational&#xD;
             drug or marketed drug within 30 days prior to initial dosing (90 days for biologics)&#xD;
             or concomitant participation in an investigational study involving no drug&#xD;
             administration.&#xD;
&#xD;
         15. Females who are breast-feeding or lactating.&#xD;
&#xD;
         16. History of pulmonary infiltrate or pneumonia (radiologically confirmed) within 6&#xD;
             months prior to initial dosing.&#xD;
&#xD;
         17. Any past exposure to recombinant human G-CSF products and/or a known history of prior&#xD;
             treatment with blood-cell colony stimulating factors, interleukins or interferons.&#xD;
&#xD;
         18. History of cancer&#xD;
&#xD;
         19. Subjects who are on a special diet or who have self-reported a weight loss of more&#xD;
             than 15 pounds within 1 month prior to initial dosing.&#xD;
&#xD;
         20. Acute viral or bacterial infection within 1 month prior to initial dosing only if&#xD;
             considered clinically significant in the opinion of the Principal&#xD;
             Investigator/designee.&#xD;
&#xD;
         21. History of any clinically significant disease or condition that, in the opinion of the&#xD;
             Principal Investigator/designee, would render them unsuitable for inclusion in the&#xD;
             study.&#xD;
&#xD;
         22. Any vaccination (including influenza) within 90 days prior to initial dosing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>WCCT Global Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Adello Biologics, LLC</investigator_affiliation>
    <investigator_full_name>Dr. Apinya Vutikullid</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Later on management will decide whether to share the data or not</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

